Company Overview
Snapshot
Founded in January 2017 by David Shashar and Avi Tsur, PregnanTech operates with 1–10 employees. The company has secured funding across 5 rounds from 6 investors.
Business overview
PregnanTech is a Health Tech & Life Sciences company focused on preventing preterm birth. The company develops the Lioness, a small, disposable device designed to maintain the natural resistance of the cervix. This device acts as a shock absorber, allowing transient cervical changes during contractions and then restoring the cervix to its initial state. PregnanTech serves the healthcare industry, specifically targeting women's health, gynecology, and medical device markets.
Strategic signal
In July 2024, PregnanTech's efforts to address the preterm birth crisis were highlighted, signaling a potential new hope in this critical area of women's health. This indicates ongoing progress and validation of their Lioness device, suggesting a positive trajectory for clinical development and market entry, which is a strong signal for investors interested in impactful medical innovations.
Log in to access full profile ›Company Intelligence Q&A
- What is PregnanTech's core product?
- PregnanTech's core product is the Lioness, a small, disposable device designed to maintain the natural resistance of the cervix to prevent preterm birth. It functions as a shock absorber, allowing for temporary cervical changes during contractions and then restoring the cervix.
- When was PregnanTech founded and by whom?
- PregnanTech was founded in January 2017 by David Shashar and Avi Tsur.
- Which investors participated in PregnanTech's February 2017 funding round?
- In February 2017, PregnanTech received funding from Sheba Medical Center and The Trendlines Group.
- What is the current development stage of the Lioness device?
- The Lioness device is currently in the clinical trial stage. PregnanTech conducted preclinical studies and began a clinical safety study in 2019 among non-pregnant women, with plans for a first clinical trial in pregnant women at risk of preterm birth.